- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03485911
Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE (APeX-2)
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX7353 as an Oral Treatment for the Prevention of Attacks in Subjects With Hereditary Angioedema
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Vienna, Austria, 1090
- Study Center
-
-
-
-
-
Québec, Canada, G1V 4W2
- Study Center
-
-
Ontario
-
Ottawa, Ontario, Canada, K1G 6C6
- Study Center
-
Toronto, Ontario, Canada, M4V 1R2
- Study Center
-
-
-
-
-
Brno, Czechia, 656 91
- Study Center
-
Plzen, Czechia, 30460
- Study Center
-
-
-
-
-
Grenoble, France, 38043
- Study Center
-
Paris, France, 75012
- Study Center
-
-
-
-
-
Berlin, Germany, 10117
- Study Center
-
Frankfurt, Germany, D-60590
- Study Center
-
-
-
-
-
Budapest, Hungary, H-1225
- Study Center
-
-
-
-
-
Skopje, North Macedonia, 1000
- Study Center
-
-
-
-
Jud. Mureș
-
Sângeorgiu de Mureș, Jud. Mureș, Romania, 547530
- Study Center
-
-
-
-
-
Barcelona, Spain, 08907
- Study Center
-
Madrid, Spain, 28046
- Study Center
-
Seville, Spain, 41013
- Study Center
-
-
-
-
-
Cambridge, United Kingdom, CB2 0QQ
- Study Center
-
Frimley, United Kingdom, GU16 7UJ
- Study Center
-
London, United Kingdom, E1 2ES
- Study Center
-
Plymouth, United Kingdom, PL6 8DH
- Study Center
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35209
- Study Center
-
-
Arizona
-
Scottsdale, Arizona, United States, 85251
- Study Center
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72205
- Study Center
-
-
California
-
San Diego, California, United States, 92122
- Study Center
-
Santa Monica, California, United States, 90404
- Study Center
-
Walnut Creek, California, United States, 94598
- Study Center
-
-
Colorado
-
Colorado Springs, Colorado, United States, 80907
- Study Center
-
-
Florida
-
Tampa, Florida, United States, 33613
- Study Center
-
-
Maryland
-
Chevy Chase, Maryland, United States, 20815
- Study Center
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Study Center
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48106
- Study Center
-
-
Minnesota
-
Plymouth, Minnesota, United States, 55446
- Study Center
-
-
Missouri
-
Saint Louis, Missouri, United States, 63141
- Study Center
-
-
New Jersey
-
Belleville, New Jersey, United States, 07109
- Study Center
-
Fair Lawn, New Jersey, United States, 07410
- Study Center
-
Piscataway, New Jersey, United States, 08854
- Study Center
-
-
New York
-
New York, New York, United States, 10029
- Study Center
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28277
- Study Site
-
Durham, North Carolina, United States, 27705
- Study Center
-
-
Ohio
-
Cincinnati, Ohio, United States, 45231
- Study Center
-
Columbus, Ohio, United States, 43235
- Study Center
-
-
Oregon
-
Clackamas, Oregon, United States, 97015
- Study Center
-
-
Pennsylvania
-
Hershey, Pennsylvania, United States, 17033
- Study Center
-
-
Texas
-
Austin, Texas, United States, 78731
- Study Center
-
Dallas, Texas, United States, 75231
- Study Center
-
San Antonio, Texas, United States, 78229
- Study Center
-
-
Washington
-
Spokane, Washington, United States, 99202
- Study Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Key Inclusion Criteria:
- A clinical diagnosis of hereditary angioedema Type 1 or Type 2, defined as having a C1-INH functional level and a C4 level below the lower limit of the normal (LLN) reference range, as assessed during the Screening period.
- Subject weight of ≥ 40 kg
- Access to and ability to use one or more acute medications approved by the relevant competent authority for the treatment of acute attacks of HAE
- Subjects must be medically appropriate for on-demand treatment as the sole medicinal management for their HAE during the study.
- Subjects must have a specified number of investigator-confirmed attacks during the run-in period of a maximum of 56 days from the Screening visit.
- Acceptable effective contraception
- Written informed consent
Key Exclusion Criteria:
- Pregnancy or breast-feeding
- Any clinically significant medical condition or medical history that, in the opinion of the Investigator or Sponsor, would interfere with the subject's safety or ability to participate in the study
- Any laboratory parameter abnormality that, in the opinion of the Investigator, is clinically significant and relevant for this study
- Severe hypersensitivity to multiple medicinal products or severe hypersensitivity/ anaphylaxis with unclear etiology
- Use of C1-INH within 14 days or use of androgens or tranexamic acid within 28 days prior to the Screening visit for prophylaxis of HAE attacks, or initiation of these drugs during the study
- Current participation in any other investigational drug study or received another investigational drug within 30 days of the Screening visit
- Prior enrollment in a BCX7353 study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: BCX7353 110 mg once daily
BCX7353 administered as oral capsules once daily
|
BCX7353 oral capsules administered once daily
Other Names:
|
Experimental: BCX7353 150 mg once daily
BCX7353 administered as oral capsules once daily
|
BCX7353 oral capsules administered once daily
Other Names:
|
Placebo Comparator: Placebo
Matching placebo administered as oral capsules once daily
|
Matching oral capsules administered once daily
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Part 1: The Rate of Investigator-confirmed HAE Attacks During Dosing in the Entire 24-week Treatment Period (Day 1 to Day 168)
Time Frame: 24 weeks
|
Treatment comparisons between each berotralstat dose and placebo in the rate of investigator-confirmed HAE attacks during the Part 1 dosing period were analyzed using a negative binomial model.
The number of investigator-confirmed attacks was included as the dependent variable, the treatment was included as a fixed effect, the stratification variable (baseline attack rate) was included as a covariate, and the logarithm of duration on treatment was included as an offset variable.
The estimated attack rate for each treatment group, the treatment differences expressed as the attack rate ratio (berotralstat over placebo rate ratio), and the associated 95% confidence intervals (CIs) were provided from the negative binomial model.
|
24 weeks
|
Part 2 & 3: To Evaluate the Long-term Safety and Tolerability of Berotralstat 110 and 150 mg in Subjects With HAE
Time Frame: Part 2: 24 weeks (Days 169 to 337). Part 3: 48 weeks (Days 338 to 674).
|
The safety data was assessed for the safety population, for subjects who entered Part 2 and Part 3, and includes TEAEs that began in Part 2 or 3, respectively, for these subjects.
Safety data for Part 2 and Part 3 is combined to clearly show TEAEs occurring in subjects as the proceeded through the 2 study parts.
TEAEs are defined as AEs that occurred on or after first dose of study treatment, whether in Part 1 or 2, and were assigned to the relevant treatment depending on when the TEAE began (Part 2 or Part 3 treatment).
No statistical analysis was performed on this safety data.
|
Part 2: 24 weeks (Days 169 to 337). Part 3: 48 weeks (Days 338 to 674).
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Part 1: Change From Baseline in Angioedema Quality of Life Questionnaire at Week 24 (Total Score)
Time Frame: Baseline and 24 weeks
|
Change in Quality of Life, on a 1-100 scale, where higher scores indicate more impairment and a decrease (change with a negative value) in AE-QoL questionnaire scores indicates an improvement in the subject's QoL.
The minimum clinically important difference (MCID) for the AE-QoL questionnaire is -6 (total score).
The AE-QoL is only validated for adults; however, data were collected on all adult and adolescent study subjects.
|
Baseline and 24 weeks
|
Part 1: Proportion of Days With Angioedema Symptoms Through 24 Weeks
Time Frame: 24 weeks
|
Assessment of proportion of days subjects had angioedema symptoms from expert-confirmed HAE attacks during Part 1.
|
24 weeks
|
Part 1: Rate of Expert-confirmed Angioedema Events During Dosing in the Effective Treatment Period
Time Frame: Day 8 through to 24 weeks (or or the last dose date/time in Part 1 + 24 hours for subjects who discontinued drug in Part 1)
|
The rate of expert-confirmed HAE attacks for the effective treatment period gives an analysis of the efficacy of active treatment after berotralstat had reached steady-state concentrations, given the effective half-life of 150 mg berotralstat in Study BCX7353-106 (Study 106) of 89 hours.
|
Day 8 through to 24 weeks (or or the last dose date/time in Part 1 + 24 hours for subjects who discontinued drug in Part 1)
|
Part 2: To Assess the Effectiveness of Berotralstat Over a 24- to 48 Week Period
Time Frame: 24 weeks (Days 169 to 337)
|
Monthly Attack Rate was defined as the total number of investigator-confirmed HAE attacks experienced during the treatment period adjusted for the length of a month (defined as 28 days) and the number of days the subject was on treatment during that month. The end of Month 6 was defined as the start of Part 2 treatment. Baseline investigator-confirmed attack rate was defined as the total number of investigator-confirmed HAE attacks experienced in the period between screening and first dose of study drug adjusted for the length of a month (defined as 28 days) and the number of days during that period. |
24 weeks (Days 169 to 337)
|
To Evaluate Angioedema Quality of Life Questionnaire (Total Score) Following Berotralstat Administration for up to 144 Weeks
Time Frame: Up to 144 weeks
|
Angioedema-specific QoL was assessed by the AE-QoL, consisting of 4 domains (i.e., functioning, fatigue/mood, fears/shame, and nutrition) and a total score.
The AE-QoL scores range from 0 points (best QoL) to 100 points (worst QoL).
A decrease (change with a negative value) in AE-QoL questionnaire scores indicates an improvement in the subject's QoL.
The minimum clinically important difference (MCID) for the AE-QoL questionnaire is -6 (total score).
The AE-QoL was completed by the subjects at each visit starting at baseline, and questions were answered with regard to the previous 28 days.
For subjects who received active treatment following placebo, visits were adjusted according to the date of the first dose of active treatment.
|
Up to 144 weeks
|
To Evaluate Treatment Satisfaction Questionnaire for Medication (TSQM) Following Berotralstat Administration for up to 144 Weeks
Time Frame: Up to 144 weeks
|
The Treatment Satisfaction Questionnaire for Medication (TSQM) was completed by subjects at baseline and at each study visit until the end of the study.
TSQM scores consisted of 14 items of which 13 items were made up of 3 specific scales (Effectiveness, Side Effects, and Convenience) and 1 global satisfaction scale (Global Satisfaction).
At baseline, TSQM questionnaires were completed based on subject's satisfaction with usual medications.
At all other time points for collection of TSQM, subjects were asked about their level of satisfaction or dissatisfaction with the study drug.
Scales scores were calculated for each scale and were transformed into scores ranging from 0 to 100, with higher scores indicating higher satisfaction.
TSQM score and corresponding change from baseline values were calculated at each visit.
For subjects who received active treatment following placebo, visits were adjusted according to the date of the first dose of active treatment.
|
Up to 144 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Bruce Zuraw, MD, UC San Diego School of Medicine, US HAE Angioedema Center
Publications and helpful links
General Publications
- Beard N, Frese M, Smertina E, Mere P, Katelaris C, Mills K. Interventions for the long-term prevention of hereditary angioedema attacks. Cochrane Database Syst Rev. 2022 Nov 3;11(11):CD013403. doi: 10.1002/14651858.CD013403.pub2.
- Wedner HJ, Aygoren-Pursun E, Bernstein J, Craig T, Gower R, Jacobs JS, Johnston DT, Lumry WR, Zuraw BL, Best JM, Iocca HA, Murray SC, Desai B, Nagy E, Sheridan WP, Kiani-Alikhan S. Randomized Trial of the Efficacy and Safety of Berotralstat (BCX7353) as an Oral Prophylactic Therapy for Hereditary Angioedema: Results of APeX-2 Through 48 Weeks (Part 2). J Allergy Clin Immunol Pract. 2021 Jun;9(6):2305-2314.e4. doi: 10.1016/j.jaip.2021.03.057. Epub 2021 Apr 15.
- Zuraw B, Lumry WR, Johnston DT, Aygoren-Pursun E, Banerji A, Bernstein JA, Christiansen SC, Jacobs JS, Sitz KV, Gower RG, Gagnon R, Wedner HJ, Kinaciyan T, Hakl R, Hanzlikova J, Anderson JT, McNeil DL, Fritz SB, Yang WH, Tachdjian R, Busse PJ, Craig TJ, Li HH, Farkas H, Best JM, Clemons D, Cornpropst M, Dobo SM, Iocca HA, Kargl D, Nagy E, Murray SC, Collis P, Sheridan WP, Maurer M, Riedl MA. Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: A randomized, double-blind, placebo-controlled phase 3 trial. J Allergy Clin Immunol. 2021 Jul;148(1):164-172.e9. doi: 10.1016/j.jaci.2020.10.015. Epub 2020 Oct 21.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Skin Diseases
- Immunologic Deficiency Syndromes
- Immune System Diseases
- Hypersensitivity, Immediate
- Genetic Diseases, Inborn
- Skin Diseases, Vascular
- Hypersensitivity
- Urticaria
- Hereditary Complement Deficiency Diseases
- Primary Immunodeficiency Diseases
- Angioedema
- Angioedemas, Hereditary
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Protease Inhibitors
- Serine Proteinase Inhibitors
- Berotralstat
Other Study ID Numbers
- BCX7353-302
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hereditary Angioedema
-
Pharvaris Netherlands B.V.Active, not recruitingHereditary Angioedema | Hereditary Angioedema Type I | Hereditary Angioedema Type II | Hereditary Angioedema Types I and II | Hereditary Angioedema Attack | Hereditary Angioedema With C1 Esterase Inhibitor Deficiency | Hereditary Angioedema - Type 1 | Hereditary Angioedema - Type 2 | C1 Esterase Inhibitor... and other conditionsUnited States, Poland, Germany, Austria, Bulgaria, Canada, Ireland, Italy, United Kingdom
-
Pharvaris Netherlands B.V.CompletedHereditary Angioedema | Hereditary Angioedema Type I | Hereditary Angioedema Type II | Hereditary Angioedema Types I and II | Hereditary Angioedema Attack | Hereditary Angioedema With C1 Esterase Inhibitor Deficiency | Hereditary Angioedema - Type 1 | Hereditary Angioedema - Type 2 | C1 Esterase Inhibitor... and other conditionsBulgaria, United States, Spain, Israel, Germany, Canada, Czechia, France, Hungary, Italy, Netherlands, Poland, United Kingdom
-
Pharvaris Netherlands B.V.RecruitingHereditary Angioedema | Hereditary Angioedema Type I | Hereditary Angioedema Type II | Hereditary Angioedema Types I and II | Hereditary Angioedema Attack | Hereditary Angioedema With C1 Esterase Inhibitor Deficiency | Hereditary Angioedema - Type 1 | Hereditary Angioedema - Type 2 | C1 Esterase Inhibitor... and other conditionsUnited States
-
Pharvaris Netherlands B.V.RecruitingHereditary Angioedema | Hereditary Angioedema Type I | Hereditary Angioedema Type II | Hereditary Angioedema Types I and II | Hereditary Angioedema Attack | Hereditary Angioedema With C1 Esterase Inhibitor Deficiency | Hereditary Angioedema - Type 1 | Hereditary Angioedema - Type 2 | C1 Esterase Inhibitor... and other conditionsUnited States, Bulgaria, Czechia, Hungary, Spain, France, Germany, Poland, Canada, Israel
-
CENTOGENE GmbH RostockCompletedHereditary Angioedema | Hereditary Angioedema Type I | Hereditary Angioedema Type II | C1 Esterase Inhibitor Deficiency | HAE | Angio Edema | C4 Deficiency | Hereditary Angioedema Type IIITurkey, Armenia, Georgia, India, Peru, Poland, Romania
-
HAE Global Registry FoundationRecruitingHereditary Angioedema Type I and IIItaly
-
KalVista Pharmaceuticals, Ltd.CompletedHereditary AngioedemaUnited States, Austria, Czechia, Germany, Hungary, Italy, Netherlands, North Macedonia, Poland, United Kingdom
-
Prothya BiosolutionsCompletedHereditary Angioedema Type I | Angioneurotic EdemaNetherlands
-
TakedaNot yet recruitingHereditary Angioedema (HAE)
-
CSL BehringRecruitingHereditary Angioedema (HAE)United States, Israel
Clinical Trials on BCX7353 capsules
-
BioCryst PharmaceuticalsCompletedHereditary Angioedema, HAEJapan
-
BioCryst PharmaceuticalsCompleted
-
BioCryst PharmaceuticalsCompletedHereditary AngioedemaUnited Kingdom
-
BioCryst PharmaceuticalsCompletedHereditary AngioedemaUnited Kingdom
-
BioCryst PharmaceuticalsApproved for marketingHereditary Angioedema | Prophylaxis | HAE
-
Reata, a wholly owned subsidiary of BiogenAbbVie; Friedreich's Ataxia Research AllianceActive, not recruitingFriedreich AtaxiaUnited States, Australia, Austria, Italy, United Kingdom
-
Reata, a wholly owned subsidiary of BiogenAbbVieCompletedMItochondrial MyopathiesUnited States, Denmark
-
Reata, a wholly owned subsidiary of BiogenTerminatedConnective Tissue Disease-Associated Pulmonary Arterial HypertensionUnited States, Spain, Japan, Australia, United Kingdom, Canada, Germany, Belgium, Argentina, Israel, Mexico, Brazil, Czechia, Netherlands, Philippines
-
BioCryst PharmaceuticalsCompletedHereditary Angioedema | Prophylaxis | HAEAustria, Denmark, France, Germany, Hungary, Israel, Italy, North Macedonia, Poland, Switzerland, United Kingdom, United States, Australia, Hong Kong, Korea, Republic of, New Zealand, Serbia, Slovakia, South Africa, Spain
-
Chinese Academy of Medical Sciences, Fuwai HospitalNot yet recruiting